HC Wainwright reaffirmed their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Friday. The firm currently has a $6.00 target price on the biopharmaceutical company’s stock.

“Our price target of $6/share is based on an equally weighted composite of: (a) $6.62/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.57 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2018-2024 of $4.46/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Firdapse to secure regulatory approval in the US; and (2) failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.”,” the firm’s analyst commented.

Several other equities research analysts have also weighed in on the stock. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, September 27th. Cantor Fitzgerald started coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, September 20th. They set an overweight rating and a $8.00 price objective on the stock. Piper Jaffray Companies started coverage on shares of Catalyst Pharmaceuticals in a research note on Friday, September 7th. They set an overweight rating and a $5.00 price objective on the stock. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $3.25 price objective on the stock in a research note on Monday, August 13th. Finally, Oppenheimer set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, October 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Catalyst Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $5.71.

CPRX traded down $0.20 on Friday, hitting $2.88. 2,952,137 shares of the company’s stock were exchanged, compared to its average volume of 1,101,016. The firm has a market cap of $323.19 million, a price-to-earnings ratio of -13.71 and a beta of 2.05. Catalyst Pharmaceuticals has a twelve month low of $2.18 and a twelve month high of $4.51.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Equities analysts anticipate that Catalyst Pharmaceuticals will post -0.29 EPS for the current year.

Several large investors have recently made changes to their positions in CPRX. Northern Trust Corp increased its stake in shares of Catalyst Pharmaceuticals by 22.5% in the first quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock valued at $2,414,000 after purchasing an additional 185,639 shares during the period. BlackRock Inc. increased its stake in shares of Catalyst Pharmaceuticals by 16.9% in the first quarter. BlackRock Inc. now owns 4,698,531 shares of the biopharmaceutical company’s stock valued at $11,230,000 after purchasing an additional 678,950 shares during the period. California State Teachers Retirement System increased its stake in shares of Catalyst Pharmaceuticals by 18.2% in the first quarter. California State Teachers Retirement System now owns 133,262 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 20,484 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $476,000. Finally, Rhumbline Advisers increased its stake in shares of Catalyst Pharmaceuticals by 34.7% in the second quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 23,383 shares during the period. Institutional investors own 51.48% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.